Entrepreneur in Residence

The Opportunity: Be an entrepreneur-in-residence to research the opportunity to build a company with AION Labs

The problem we’re trying to solve?

The challenge, as defined by AION Labs’ partners, led by Teva Pharmaceuticals, is to reduce the number of control patients needed in clinical trials. This will be facilitated by computationally matching control patients from a shared pool of control patient datasets from past clinical trials, leveraging the sharing of data in a federated environment from AION Labs pharma partners and other sources.

Previous attempts to produce synthetic patient cohorts have been based on real world evidence (RWE) to reduce the number of patients needed in clinical trials. While promising, RWE differs from clinical trials in data collection, combination of treatments and measurable endpoints. In contrast, control arms from previous clinical trials can provide the best data source for modeling clinical trial outcomes with the standard of care, assuming the data becomes accessible.

The solution envisioned will be centered around a pool of control patients for various clinical indications, based on historical and current real patient data. The clinical data will be stored with all relevant data commonly collected from clinical trials (inclusion/exclusion data, primary and secondary readouts). When conducting a clinical study, pharma companies will recruit a treatment arm and a smaller control arm.

The AI matching solution will expand the selected control arm from the existing pool of shared patients based on the study protocol and the existing arms in the study. We expect the solution to include cohort matching metrics and potential suggested changes to the study protocol that will increase these metrics to enhance confidence in the suitability of the cohort expansion.

What we are looking for

We are seeking an experienced entrepreneur with an outstanding track record and history of successful ventures and passion for the space. Those with a strong interest in the fields of machine learning, language models, clinical studies, computational biology or other relevant fields, are invited to apply for an opportunity to join our team as an Entrepreneur In Residence (EIR).

The successful EIR will build a comprehensive business plan within a six-month period of starting at AION Labs. During this period the AION Labs team and partners will be available to work with the EIR until a final plan is formulated and presented to the investment committee for approval. We expect the plan to address the following:

• Fine tune the problem statement and market research.
• Define the business model that will create incentives for pharma companies to provide access to their control arm data.
• Suggest a pharma compliant data infrastructure.
• Suggest a regulatory and legal framework for reducing control arms in clinical trials.
• Define a business model including competitive landscape, market fit and go-to-market strategy.
• Suggest a novel technological solution for augmenting control arms with data from previous control patients.
• Scan the competitive landscape for existing solutions, identify their limitations and suggest a novel strategy and technology.

How to apply and selection process

• Please submit to: [email protected] : (i) Your CV including your publication/track record. (ii) a cover letter describing your envisioned approach of studying this field as the EIR.
• Selected candidates will be invited for an interview with the AION Labs team and selected strategic partners.
• The selected EIR will have six months to prepare for an Investment Committee meeting to secure a pre-seed investment offer.

About AION Labs

AION Labs is a first-of-its-kind venture studio comprising AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and Amazon Web Services (AWS), powered by BioMed X with the support of the Israel Innovation Authority, that have come together with one clear mission: to create and adopt groundbreaking new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.